A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 [panobinostat] when administered in combination with oral lenalidomide and dexamethasone in adult patients with multiple myeloma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2017
At a glance
- Drugs Panobinostat (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Novartis
- 10 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
- 10 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
- 02 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.